Piper Sandler raised the firm’s price target on Prometheus to $138 from $114 and keeps an Overweight rating on the shares. The analyst continues to be bullish on the name as it prepares to initiate Phase 3 studies in 2023. The firm says Prometheus is entering a "catalyst rich" 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXDX:
- Prometheus price target raised to $150 from $125 at Oppenheimer
- Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
- Prometheus reports Q4 EPS (90c), consensus (92c)
- Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)
- Looking for Powerful Healthcare Stocks? These 5 Made Enormous Profit in 2022
